Len Blavatnik has an estimated net worth of $12.6 Billion. This is based on reported shares across multiple companies, which include LyondellBasell Industries N.V., Warner Music Group Corp., Square, Inc., Day One Biopharmaceuticals, Inc., Eliem Therapeutics, Inc., Gamida Cell Ltd., DigitalOcean Holdings, Inc., Neon Therapeutics, Inc., Loxo Oncology, Inc., EP Energy Corp, Anchiano Therapeutics Ltd., Verona Pharma plc, Disc Medicine, Inc., Pandion Therapeutics Holdco LLC, VYNE Therapeutics Inc., Upstream Bio, Inc., Zura Bio Ltd, Hemab Therapeutics Holdings, Inc., and OnKure Therapeutics, Inc..

2018 was Len Blavatnik's most active year for acquiring shares with 22 total transactions. Len Blavatnik's most active month to acquire stocks was the month of October. 2021 was Len Blavatnik's most active year for disposing of shares, totalling 93 transactions. Len Blavatnik's most active month to dispose stocks was the month of January. 2011 saw Len Blavatnik paying a total of $962,666,880.00 for 34,380,960 shares, this is the most they've acquired in one year. In 2020 Len Blavatnik cashed out on 178,634,046 shares for a total of $1,849,173,971.25, their largest year based on trade value.